Spots Global Cancer Trial Database for fluorescence in situ hybridization
Every month we try and update this database with for fluorescence in situ hybridization cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | NCT00546377 | Leukemia Lymphoma | filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | NCT00655499 | Colorectal Canc... | Panitumumab Irinotecan hydr... Chromogenic in ... Fluorescence in... Gene expression... Laboratory biom... | 18 Years - 80 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy | NCT01194635 | Head and Neck C... | fluorescence in... gene expression... polymerase chai... protein analysi... protein express... enzyme-linked i... immunohistochem... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors | NCT01544569 | Kidney Cancer | DNA analysis fluorescence in... gene expression... gene mapping microarray anal... polymerase chai... protein express... laboratory biom... medical chart r... | - 1 Year | Children's Oncology Group | |
| Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer. | NCT00611715 | Breast Cancer | erlotinib hydro... letrozole fluorescence in... immunohistochem... laboratory biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers | NCT01139983 | Sarcoma | DNA analysis RNA analysis fluorescence in... microarray anal... polymerase chai... reverse transcr... laboratory biom... | - | Children's Oncology Group | |
| Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia | NCT01284010 | Leukemia | DNA analysis fluorescence in... gene expression... microarray anal... mutation analys... polymerase chai... laboratory biom... | 16 Years - | Alliance for Clinical Trials in Oncology | |
| Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma | NCT00049010 | Melanoma (Skin) | comparative gen... cytogenetic ana... fluorescence in... immunohistochem... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | NCT00499655 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | erlotinib hydro... celecoxib placebo laboratory biom... immunohistochem... fluorescence in... mutation analys... protein express... gene expression... | 18 Years - | City of Hope Medical Center | |
| DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia | NCT00897936 | Leukemia | DNA methylation... comparative gen... fluorescence in... microarray anal... polymerase chai... diagnostic labo... immunologic tec... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Biomarkers in Patients With Rhabdomyosarcoma | NCT01466283 | Sarcoma | DNA methylation... fluorescence in... gene expression... reverse transcr... laboratory biom... | - | Children's Oncology Group | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx | NCT00498953 | Head and Neck C... | carboplatin cisplatin docetaxel fluorouracil lapatinib ditos... cytogenetic ana... fluorescence in... in situ hybridi... polymerase chai... reverse transcr... immunohistochem... laboratory biom... conventional su... neoadjuvant the... fludeoxyglucose... radiation thera... | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia | NCT01284010 | Leukemia | DNA analysis fluorescence in... gene expression... microarray anal... mutation analys... polymerase chai... laboratory biom... | 16 Years - | Alliance for Clinical Trials in Oncology | |
| Molecular Characterization of Perivascular Epithelioid Cell Tumors | NCT05617105 | Perivascular Ep... | 1 Year - | University Hospital, Strasbourg, France | ||
| Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | NCT00655499 | Colorectal Canc... | Panitumumab Irinotecan hydr... Chromogenic in ... Fluorescence in... Gene expression... Laboratory biom... | 18 Years - 80 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients | NCT02010047 | Nonsmall Cell L... | ALK qPCR assay | 19 Years - | British Columbia Cancer Agency | |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | NCT01269385 | B-cell Chronic ... Refractory Chro... Stage 0 Chronic... Stage I Chronic... Stage II Chroni... | alemtuzumab rituximab PGG beta-glucan flow cytometry laboratory biom... DNA analysis fluorescence in... polymerase chai... polymorphism an... mutation analys... | 18 Years - | Mayo Clinic | |
| Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507 | NCT00907699 | Lung Cancer | DNA analysis RNA analysis fluorescence in... gene expression... mutation analys... polymerase chai... reverse transcr... laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | NCT00499655 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | erlotinib hydro... celecoxib placebo laboratory biom... immunohistochem... fluorescence in... mutation analys... protein express... gene expression... | 18 Years - | City of Hope Medical Center | |
| Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia | NCT01653613 | Leukemia | DNA analysis fluorescence in... gene expression... microarray anal... mutation analys... polymorphism an... reverse transcr... laboratory biom... | 16 Years - 39 Years | National Cancer Institute (NCI) | |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | NCT00551421 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... | pertuzumab cetuximab irinotecan hydr... immunohistochem... fluorescence in... gene expression... mutation analys... polymerase chai... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | NCT01251250 | Refractory Chro... Stage II Chroni... Stage III Chron... Stage IV Chroni... | laboratory biom... western blottin... gene expression... pharmacological... flow cytometry fluorescence in... azadirachta ind... reverse transcr... | 18 Years - | Roswell Park Cancer Institute | |
| CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 | NCT00812669 | Leukemia | pegfilgrastim rituximab cyclophosphamid... fludarabine pho... cytogenetic ana... fluorescence in... gene expression... mutation analys... protein express... flow cytometry laboratory biom... | 0 Years - 64 Years | Cancer Trials Ireland | |
| Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy | NCT01194635 | Head and Neck C... | fluorescence in... gene expression... polymerase chai... protein analysi... protein express... enzyme-linked i... immunohistochem... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery | NCT00646659 | Head and Neck C... | cetuximab carboplatin cisplatin docetaxel fluorouracil fluorescence in... molecular genet... reverse transcr... immunoenzyme te... immunohistochem... laboratory biom... biopsy 3-dimensional c... intensity-modul... | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia | NCT00769327 | Leukemia | imatinib mesyla... nilotinib cytogenetic ana... fluorescence in... microarray anal... mutation analys... polymerase chai... polymorphism an... laboratory biom... | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | NCT01382706 | Recurrent Bladd... Stage III Bladd... Stage IV Bladde... Transitional Ce... | docetaxel lapatinib ditos... immunohistochem... fluorescence in... laboratory biom... | 18 Years - | University of Southern California | |
| DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia | NCT00897936 | Leukemia | DNA methylation... comparative gen... fluorescence in... microarray anal... polymerase chai... diagnostic labo... immunologic tec... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia | NCT01653613 | Leukemia | DNA analysis fluorescence in... gene expression... microarray anal... mutation analys... polymorphism an... reverse transcr... laboratory biom... | 16 Years - 39 Years | National Cancer Institute (NCI) | |
| Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery | NCT00646659 | Head and Neck C... | cetuximab carboplatin cisplatin docetaxel fluorouracil fluorescence in... molecular genet... reverse transcr... immunoenzyme te... immunohistochem... laboratory biom... biopsy 3-dimensional c... intensity-modul... | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission | NCT00458523 | Leukemia | alemtuzumab fluorescence in... mutation analys... flow cytometry | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma | NCT00466687 | Melanoma | bevacizumab erlotinib hydro... fluorescence in... gene expression... immunologic tec... laboratory biom... biopsy | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma | NCT00360945 | Brain and Centr... | cisplatin temozolomide fluorescence in... loss of heteroz... immunohistochem... laboratory biom... radiation thera... | 4 Years - 20 Years | National Cancer Institute (NCI) | |
| Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | NCT00845104 | B-cell Chronic ... Refractory Chro... | fludarabine pho... rituximab bevacizumab laboratory biom... flow cytometry polymerase chai... fluorescence in... | 18 Years - | Fred Hutchinson Cancer Center | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery | NCT00671476 | Breast Cancer | pegylated lipos... DNA methylation... TdT-mediated dU... fluorescence in... loss of heteroz... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... breast duct lav... neoadjuvant the... therapeutic con... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer | NCT00975897 | Colorectal Canc... | bevacizumab cetuximab fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin RNA analysis cytogenetic ana... fluorescence in... gene expression... mutation analys... protein express... diagnostic labo... immunohistochem... questionnaire a... cognitive asses... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Proteases in Patients With Prostate Cancer That Has Spread to the Bone | NCT00899665 | Anemia Metastatic Canc... Myelodysplastic... Precancerous Co... Prostate Cancer | fluorescence in... microarray anal... molecular diagn... immunohistochem... laboratory biom... biopsy immunoscintigra... | 40 Years - | Barbara Ann Karmanos Cancer Institute | |
| Lapatinib Resistance in Patients With Breast Cancer | NCT00898573 | Breast Cancer | lapatinib ditos... fluorescence in... gene expression... mutation analys... polymerase chai... reverse transcr... cell sorting immunohistochem... laboratory biom... | - | Case Comprehensive Cancer Center | |
| Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma | NCT00466687 | Melanoma | bevacizumab erlotinib hydro... fluorescence in... gene expression... immunologic tec... laboratory biom... biopsy | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma | NCT00217438 | Refractory Mult... Stage II Multip... Stage III Multi... | melphalan amifostine trih... peripheral bloo... fluorescence in... bone marrow abl... | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | NCT00845104 | B-cell Chronic ... Refractory Chro... | fludarabine pho... rituximab bevacizumab laboratory biom... flow cytometry polymerase chai... fluorescence in... | 18 Years - | Fred Hutchinson Cancer Center | |
| Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma | NCT01493830 | Neuroblastoma | fluorescence in... gene expression... microarray anal... mutation analys... protein analysi... immunohistochem... laboratory biom... microscopy | - 120 Years | Children's Oncology Group | |
| Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial | NCT01424865 | Breast Cancer | fluorescence in... immunohistochem... immunologic tec... laboratory biom... | 18 Years - | NSABP Foundation Inc | |
| Markers of Response to Intravesical Bladder Cancer Therapy | NCT01007058 | Bladder Cancer | 18 Years - | M.D. Anderson Cancer Center | ||
| Molecular Characterization of Perivascular Epithelioid Cell Tumors | NCT05617105 | Perivascular Ep... | 1 Year - | University Hospital, Strasbourg, France | ||
| Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | NCT01382706 | Recurrent Bladd... Stage III Bladd... Stage IV Bladde... Transitional Ce... | docetaxel lapatinib ditos... immunohistochem... fluorescence in... laboratory biom... | 18 Years - | University of Southern California | |
| UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer | NCT00900094 | Breast Cancer Colorectal Canc... Esophageal Canc... Liver Cancer Lung Cancer Ovarian Cancer Pancreatic Canc... | fluorescence in... polymerase chai... protein express... immunohistochem... laboratory biom... mass spectromet... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer | NCT00550628 | Colorectal Canc... Neoplasm of Unc... | DNA methylation... fluorescence in... gene expression... polymerase chai... protein express... reverse transcr... diagnostic labo... immunoenzyme te... immunohistochem... biopsy therapeutic con... fludeoxyglucose... | 15 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Ductal Lavage in Women at High Risk for Breast Cancer | NCT00429988 | Breast Cancer | fluorescence in... polymerase chai... proteomic profi... cytology specim... immunohistochem... breast duct lav... | 18 Years - | University of California, San Francisco | |
| Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | NCT00845104 | B-cell Chronic ... Refractory Chro... | fludarabine pho... rituximab bevacizumab laboratory biom... flow cytometry polymerase chai... fluorescence in... | 18 Years - | Fred Hutchinson Cancer Center | |
| Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer | NCT00816413 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... Nonmalignant Ne... | cyclosporine mycophenolate m... pentostatin cytogenetic ana... fluorescence in... protein analysi... flow cytometry immunoenzyme te... laboratory biom... reduced-intensi... nonmyeloablativ... peripheral bloo... total-body irra... | 19 Years - 75 Years | University of Nebraska | |
| Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344 | NCT00897026 | Breast Cancer | cyclophosphamid... doxorubicin hyd... paclitaxel fluorescence in... immunohistochem... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | NCT00112827 | Refractory Mult... Smoldering Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | total marrow ir... melphalan peripheral bloo... filgrastim fluorescence in... cytogenetic ana... cyclophosphamid... autologous-auto... lenalidomide | - 70 Years | City of Hope Medical Center | |
| Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma | NCT00217438 | Refractory Mult... Stage II Multip... Stage III Multi... | melphalan amifostine trih... peripheral bloo... fluorescence in... bone marrow abl... | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Biomarkers in Patients With Rhabdomyosarcoma | NCT01466283 | Sarcoma | DNA methylation... fluorescence in... gene expression... reverse transcr... laboratory biom... | - | Children's Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
